Healthcare professionals recommend using the drug Blinatumomab for treating patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children. Blinatumomab is sold under the brand name Blincyto. Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 (expressed on cells of B-lineage origin) and CD3 (expressed on T cells). Blinatumomab is produced in Chinese hamster ovary cells. Blinatumomab single-dose vials in 35 mcg to administer intravenously. The active ingredient in the vials is Blinatumomab, with inactive ingredients citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, and sodium hydroxide. Blincyto price is affordable, and one can purchase this medication from licensed pharmaceutical generic medicine suppliers. For further details on Blinatumomab, dial 18008891064.